Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan
Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the ma...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861861/ https://www.ncbi.nlm.nih.gov/pubmed/24348395 http://dx.doi.org/10.1159/000356826 |
_version_ | 1782295692096569344 |
---|---|
author | Yagi, Yoshitaka Kim, Young Hak Tajima, Noriyuki Baba, Kiichiro Aihara, Kensaku Soo, Hong Hyun Yamaoka, Shinpachi Mishima, Michiaki |
author_facet | Yagi, Yoshitaka Kim, Young Hak Tajima, Noriyuki Baba, Kiichiro Aihara, Kensaku Soo, Hong Hyun Yamaoka, Shinpachi Mishima, Michiaki |
author_sort | Yagi, Yoshitaka |
collection | PubMed |
description | Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the majority of patients develop recurrence and the prognosis of such patients is reportedly 2–4 months. Evolution of the treatment for SCLC has stagnated, and cisplatin + etoposide has been the standard chemotherapy for decades. Meanwhile, the combination of cisplatin + irinotecan has demonstrated equivalent efficacy to cisplatin + etoposide. Recently, maintenance chemotherapy has been extensively investigated in non-small-cell lung cancer (NSCLC), and is currently recommended as a standard treatment in clinical guidelines. On the contrary, a maintenance strategy has not been established for SCLC. Here, we describe an SCLC patient who received maintenance chemotherapy with irinotecan for more than 2 years after induction chemotherapy with cisplatin + irinotecan, and survived long term with no recurrence. |
format | Online Article Text |
id | pubmed-3861861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-38618612013-12-13 Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan Yagi, Yoshitaka Kim, Young Hak Tajima, Noriyuki Baba, Kiichiro Aihara, Kensaku Soo, Hong Hyun Yamaoka, Shinpachi Mishima, Michiaki Case Rep Oncol Published online: November, 2013 Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized by rapid tumor growth and early metastasis to multiple organs. Response to initial chemotherapy is generally good; however, the majority of patients develop recurrence and the prognosis of such patients is reportedly 2–4 months. Evolution of the treatment for SCLC has stagnated, and cisplatin + etoposide has been the standard chemotherapy for decades. Meanwhile, the combination of cisplatin + irinotecan has demonstrated equivalent efficacy to cisplatin + etoposide. Recently, maintenance chemotherapy has been extensively investigated in non-small-cell lung cancer (NSCLC), and is currently recommended as a standard treatment in clinical guidelines. On the contrary, a maintenance strategy has not been established for SCLC. Here, we describe an SCLC patient who received maintenance chemotherapy with irinotecan for more than 2 years after induction chemotherapy with cisplatin + irinotecan, and survived long term with no recurrence. S. Karger AG 2013-11-14 /pmc/articles/PMC3861861/ /pubmed/24348395 http://dx.doi.org/10.1159/000356826 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published online: November, 2013 Yagi, Yoshitaka Kim, Young Hak Tajima, Noriyuki Baba, Kiichiro Aihara, Kensaku Soo, Hong Hyun Yamaoka, Shinpachi Mishima, Michiaki Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan |
title | Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan |
title_full | Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan |
title_fullStr | Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan |
title_full_unstemmed | Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan |
title_short | Long Survival of a Small-Cell Lung Cancer Patient Who Received Maintenance Chemotherapy with Irinotecan |
title_sort | long survival of a small-cell lung cancer patient who received maintenance chemotherapy with irinotecan |
topic | Published online: November, 2013 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861861/ https://www.ncbi.nlm.nih.gov/pubmed/24348395 http://dx.doi.org/10.1159/000356826 |
work_keys_str_mv | AT yagiyoshitaka longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT kimyounghak longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT tajimanoriyuki longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT babakiichiro longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT aiharakensaku longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT soohonghyun longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT yamaokashinpachi longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan AT mishimamichiaki longsurvivalofasmallcelllungcancerpatientwhoreceivedmaintenancechemotherapywithirinotecan |